We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ORIC

News List

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors firstwordpharma
August 17, 2021
ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors.
Oric closes funding to develop glucocorticoid antagonist ORIC-101 pharmaceutical-technology
August 12, 2019
Oric Pharmaceuticals has closed a Series D financing to support the continued development of a clinical-stage, selective and potent glucocorticoid receptor antagonist, ORIC-101.
ORIC Pharmaceuticals Appoints Chief Scientific Officer contractpharma
July 10, 2019
Lori Friedman, PhD to lead ORIC's research and preclinical development efforts.